Cargando…
Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Haleema Shakur, Ian Roberts, et al.
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797007/ https://www.ncbi.nlm.nih.gov/pubmed/19958522 http://dx.doi.org/10.1186/1745-6215-10-110 |
| _version_ | 1782175580564750336 |
|---|---|
| author | Simmon, Vincent F |
| author_facet | Simmon, Vincent F |
| author_sort | Simmon, Vincent F |
| collection | PubMed |
| description | A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Haleema Shakur, Ian Roberts, et al. |
| format | Text |
| id | pubmed-2797007 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2009 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-27970072009-12-23 Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury Simmon, Vincent F Trials Letter A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Haleema Shakur, Ian Roberts, et al. BioMed Central 2009-12-03 /pmc/articles/PMC2797007/ /pubmed/19958522 http://dx.doi.org/10.1186/1745-6215-10-110 Text en Copyright ©2009 Simmon; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter Simmon, Vincent F Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury |
| title | Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury |
| title_full | Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury |
| title_fullStr | Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury |
| title_full_unstemmed | Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury |
| title_short | Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury |
| title_sort | response to: the brain trial: a randomised, placebo controlled trial of a bradykinin b2 receptor antagonist (anatibant) in patients with traumatic brain injury |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797007/ https://www.ncbi.nlm.nih.gov/pubmed/19958522 http://dx.doi.org/10.1186/1745-6215-10-110 |
| work_keys_str_mv | AT simmonvincentf responsetothebraintrialarandomisedplacebocontrolledtrialofabradykininb2receptorantagonistanatibantinpatientswithtraumaticbraininjury |